QIAGEN Announces Supply Agreement With Roche Molecular Systems

14-Feb-2005

Qiagen GmbH, a wholly-owned subsidiary of QIAGEN N.V. announced that they have entered into a manufacturing and supply agreement with Roche Molecular Systems, a unit of Roche Diagnostics Basel, Switzerland, who will market QIAGEN's media sample preparation kits under their AmpliLute trademark.

This customized kit will incorporate a specific version of QIAGEN's well-established QIAamp(R) technology to purify DNA from specimens stored in liquid cytology media. QIAGEN's proprietary nucleic acid sample preparation and handling technologies provide high reliability and efficiency in both DNA and RNA separation and purification for molecular diagnostics applications.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

10+ products
4 whitepaper
10+ brochures
View topic world

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

10+ products
4 whitepaper
10+ brochures